Amyotrophic Lateral Sclerosis

• 

  Subject Areas on Research

  • "ALS reversals": demographics, disease characteristics, treatments, and co-morbidities. 
  • A high-density genome-wide association screen of sporadic ALS in US veterans. 
  • A molecular genetic approach to amyotrophic lateral sclerosis. 
  • A new approach for rare variation collapsing on functional protein domains implicates specific genic regions in ALS. 
  • A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. 
  • A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. 
  • A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. 
  • A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. 
  • ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. 
  • ALS Untangled No. 20: the Deanna protocol. 
  • ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. 
  • ALS untangled No. 17: "when ALS is lyme". 
  • ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy. 
  • ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. 
  • ALSUntangled #60: light therapy. 
  • ALSUntangled #61: melatonin. 
  • ALSUntangled #62: vitamin C. 
  • ALSUntangled #63: ketogenic diets. 
  • ALSUntangled #64: butyrates. 
  • ALSUntangled #65: glucocorticoid corticosteroids. 
  • ALSUntangled (ALSU): a scientific approach to off-label treatment options for people with ALS using tweets and twitters. 
  • ALSUntangled 15: coconut Oil. 
  • ALSUntangled 38: L-serine. 
  • ALSUntangled 41: "Eric Is Winning". 
  • ALSUntangled 42: Elysium health's "basis". 
  • ALSUntangled 43: copper. 
  • ALSUntangled 44: curcumin. 
  • ALSUntangled 46: penicillin G/hydrocortisone. 
  • ALSUntangled 48: Perampanel (Fycompa). 
  • ALSUntangled 56: "ten red flags"-things to be wary of in alternative or off-label products. 
  • ALSUntangled 57: Vinpocetine. 
  • ALSUntangled 59: Tamoxifen. 
  • ALSUntangled No. 16: cannabis. 
  • ALSUntangled No. 26: lunasin. 
  • ALSUntangled No. 29: MitoQ. 
  • ALSUntangled No. 34: GM604. 
  • ALSUntangled No. 35: Hyperbaric Oxygen Therapy. 
  • ALSUntangled No. 36: Accilion. 
  • ALSUntangled No. 37: Inosine. 
  • ALSUntangled No. 47: RT001. 
  • ALSUntangled: introducing The Table of Evidence. 
  • Abnormal sensory evoked potentials in amyotrophic lateral sclerosis. 
  • Acetylcholinesterase inhibition and Gulf War illnesses: conclusions are not supported by independent reviews of the same evidence. 
  • Acylation of Superoxide Dismutase 1 (SOD1) at K122 Governs SOD1-Mediated Inhibition of Mitochondrial Respiration. 
  • Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. 
  • Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. 
  • Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review. 
  • Amyotrophic lateral sclerosis among 1991 Gulf War veterans: evidence for a time-limited outbreak. 
  • Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. 
  • Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genes. 
  • Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. 
  • Amyotrophic lateral sclerosis: current practice and future treatments. 
  • An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. 
  • Apolipoprotein E and neuromuscular disease: a critical review of the literature. 
  • Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. 
  • Assessment of aspiration risk in stroke patients with quantification of voluntary cough. 
  • Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. 
  • Association between blood lead and the risk of amyotrophic lateral sclerosis. 
  • Association of ALS with head injury, cigarette smoking and APOE genotypes. 
  • Automatic analysis of the electromyographic interference pattern. Part II: Findings in control subjects and in some neuromuscular diseases. 
  • Autophagy and mitophagy in ALS. 
  • Biomarkers for amyotrophic lateral sclerosis. 
  • Blood Lead, Bone Turnover, and Survival in Amyotrophic Lateral Sclerosis. 
  • Blood levels of trace metals and amyotrophic lateral sclerosis. 
  • Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans. 
  • COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis. 
  • Can we eliminate placebo in ALS clinical trials? 
  • Cell death in age-related macular degeneration. 
  • Characteristics associated with participation in DNA banking: The National Registry of Veterans with ALS. 
  • Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. 
  • Clinical aspects of ALS in Gulf War veterans. 
  • Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. 
  • Collagenolytic activity of the skin associated with neuromuscular diseases including amyotrophic lateral sclerosis. 
  • Compassionate use of stem cells for ALS: popovers and hot air. 
  • Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis. 
  • Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. 
  • Continuing Non-Invasive Ventilation During Amyotrophic Lateral Sclerosis-Related Hospice Care Is Medically, Administratively, and Financially Feasible. 
  • Creatine for amyotrophic lateral sclerosis/motor neuron disease. 
  • Creatine for amyotrophic lateral sclerosis/motor neuron disease. 
  • Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. 
  • Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study 
  • Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). 
  • Diaphragm pacing in amyotrophic lateral sclerosis: a literature review. 
  • Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. 
  • Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. 
  • Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. 
  • Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. 
  • Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study. 
  • Estimating the occurrence of amyotrophic lateral sclerosis among Gulf War (1990-1991) veterans using capture-recapture methods. 
  • Evaluating Brain-Computer Interface Performance in an ALS Population: Checkerboard and Color Paradigms. 
  • Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. 
  • Factors associated with survival in the National Registry of Veterans with ALS. 
  • Fas(t) balls and Lou Gehrig disease. A clue to selective vulnerability of motor neurons? 
  • Focused goodness of fit tests for gene set analyses. 
  • Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics. 
  • Genetic Correction of SOD1 Mutant iPSCs Reveals ERK and JNK Activated AP1 as a Driver of Neurodegeneration in Amyotrophic Lateral Sclerosis. 
  • Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. 
  • Historical controls in ALS trials: a high seas rescue? 
  • How common are ALS plateaus and reversals? 
  • Human genetics. Did radicals strike Lou Gehrig? 
  • IPLEX and the telephone game: the difficulty in separating myth from reality on the internet. 
  • Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. 
  • Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. 
  • Incorporating external information to improve sparse signal detection in rare-variant gene-set-based analyses. 
  • Increasing BCI communication rates with dynamic stopping towards more practical use: an ALS study. 
  • Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis. 
  • Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19. 
  • Infrastructure resources for clinical research in amyotrophic lateral sclerosis. 
  • Intralingual Administration of AAVrh10-miRSOD1 Improves Respiratory But Not Swallowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis. 
  • Intronic NEFH variant is associated with reduced risk for sporadic ALS and later age of disease onset. 
  • Joint modeling of multiple repeated measures and survival data using multidimensional latent trait linear mixed model. 
  • LATE-NC staging in routine neuropathologic diagnosis: an update. 
  • Laboratory testing for lyme neuroborreliosis--reply. 
  • Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis. 
  • Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. 
  • Linkage analysis in familial amyotrophic lateral sclerosis. 
  • Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. 
  • Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. 
  • Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. 
  • Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed. 
  • Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients. 
  • Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes. 
  • Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. 
  • Lyme disease serology in amyotrophic lateral sclerosis. 
  • Lyme disease: authentic imitator or wishful imitation? 
  • MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. 
  • Macular sub-layer thinning and association with pulmonary function tests in Amyotrophic Lateral Sclerosis. 
  • Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. 
  • Microglial activation in an amyotrophic lateral sclerosis-like model caused by Ranbp2 loss and nucleocytoplasmic transport impairment in retinal ganglion neurons. 
  • Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology. 
  • Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis survival. 
  • Mitochondria in sporadic amyotrophic lateral sclerosis. 
  • Modifiable barriers to enrollment in American ALS research studies. 
  • Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes. 
  • Neuromuscular Disease in the Neurointensive Care Unit. 
  • Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. 
  • Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. 
  • Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. 
  • Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review. 
  • Palliative treatment of dysphonia and dysarthria. 
  • Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. 
  • Peer recommendations on how to improve clinical research, and Conference wrap-up. 
  • Perspective: Untangling the ALS X-Files. 
  • Pesticide exposure and amyotrophic lateral sclerosis. 
  • Phase 2 study of sodium phenylbutyrate in ALS. 
  • Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses. 
  • Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. 
  • Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. 
  • Quality Control in Neurons: Mitophagy and Other Selective Autophagy Mechanisms. 
  • Quantifying neuromuscular ultrasound in amyotrophic lateral sclerosis. 
  • Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. 
  • Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism. 
  • Respiratory pathology in the Optn-/- mouse model of Amyotrophic Lateral Sclerosis. 
  • Restrictive Lung Disease in the Cu/Zn Superoxide-Dismutase 1 G93A Amyotrophic Lateral Sclerosis Mouse Model. 
  • Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease. 
  • Roaring in the ears: patulous Eustachian tube in bulbar amyotrophic lateral sclerosis. 
  • Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. 
  • Scrutinizing enrollment in ALS clinical trials: room for improvement? 
  • Senataxin mutations elicit motor neuron degeneration phenotypes and yield TDP-43 mislocalization in ALS4 mice and human patients. 
  • Spatial analysis of the etiology of amyotrophic lateral sclerosis among 1991 Gulf War veterans. 
  • Spinal cord gray matter segmentation using deep dilated convolutions. 
  • Study of "ALS reversals": LifeTime environmental exposures (StARLiTE). 
  • Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. 
  • Syncoilin modulates peripherin filament networks and is necessary for large-calibre motor neurons. 
  • Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. 
  • The National Registry of Veterans with Amyotrophic Lateral Sclerosis: Department of Veterans Affairs Cooperative Studies Program (CSP) #500a. 
  • The National Registry of Veterans with amyotrophic lateral sclerosis. 
  • The Role of Endoscopic Management in Afferent Loop Syndrome. 
  • The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma. 
  • The coming-of-age of nucleocytoplasmic transport in motor neuron disease and neurodegeneration. 
  • The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. 
  • The gene encoding the glutamate receptor subunit GluR5 is located on human chromosome 21q21.1-22.1 in the vicinity of the gene for familial amyotrophic lateral sclerosis. 
  • Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. 
  • Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis. 
  • Total serum immunoglobulin A in ALS. 
  • Transmissibility of the Ice Bucket Challenge among globally influential celebrities: retrospective cohort study. 
  • ULTRASOUND IN THE DIAGNOSIS AND MONITORING OF AMYOTROPHIC LATERAL SCLEROSIS: A REVIEW. 
  • Uncoupling of Protein Aggregation and Neurodegeneration in a Mouse Amyotrophic Lateral Sclerosis Model. 
  • Understanding the needs of people with ALS: a national survey of patients and caregivers. 
  • Using the detectability index to predict P300 speller performance. 
  • Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis. 
  • Veterans Affairs Research and Development: using science to improve health care for veterans. 
• 

  Keywords of People

  • ElMallah, Mai, Associate Professor of Pediatrics, Cell Biology
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics